Company | Market Cap (USD) |
---|---|
Lilly | $689.42 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $487.54 B |
Johnson & Johnson | $353.05 B |
AbbVie | $301.60 B |
Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, other European Countries, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to license partners, pharmaceutical wholesalers, pharmacies, and hospitals. Photocure ASA was founded in 1997 and is headquartered in Oslo, Norway.
PhotoCure ASA has the following listings and related stock indices.
Stock: OSE: PHO wb_incandescent
Stock: OSE: PHOO wb_incandescent
Stock: FSX: PHS wb_incandescent
Stock: OTC: PHCUF wb_incandescent